Stakeholders increasingly highlight the need for better, more standardized tools to validate and compare liquid biopsy tests, and commercial firms have responded.
The technology is based on helitrons, a type of eukaryotic transposon that can incorporate multiple copies of a DNA sequence into a genome.
The deal covers Atum's custom vectors and Horizon's CHO Source biomanufacturing platform.
The firm has secured rights to use CRISPR in cell lines for biomanufacturing and will work with Solentim to increase editing throughput while decreasing costs.
The partnership aims to improve cancer molecular profiling by combining Horizon's HDx reference standards with Sophia's artificial intelligence solution.
Horizon will supply cell-free DNA-based molecular reference standards for inclusion in CareDx’s cfDNA testing workflows for the monitoring of transplanted organ rejection.
Horizon Discovery, Desktop Genetics, and Vectalys will work together to create fully-licensed, customizable kits for CRISPR/Cas9-based genetic screening.
Revenues increased on gains in product sales, which helped offset a decline in molecular screening revenues.
Cell line engineers from Horizon Genomics said a method to make or undo fusion oncogenes in cell lines could help create reference standards for cancer diagnostics.
Fulcrum, a startup pharmaceutical company, is looking for druggable targets to regulate gene expression in genetic diseases where few treatment options exist.
Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.
Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.
China is embracing preimplantation genetic diagnosis, Nature News reports.
In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.